AbbVie announced plans to acquire Immunogen — and the biotech’s recently approved ADC treatment for ovarian cancer — for $10.1 billion in cash. The pharma giant is diving into ADCs again after a previous multibillion-dollar acquisition of a different ADC drugmaker ended up failing a few years ago.
The deal will broaden Merck's oncology portfolio as it picks up an antibody-drug conjugate, a class of biological drugs that target tumor cells even as the pharma giant jettisons other parts of its business
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The companies will share development and commercialization of DS-1062 in solid tumors. They already have a similar deal in place, the $6.9 billion agreement signed last year for another ADC, the HER2-positive breast cancer drug Enhertu.
Arix Bioscience co-leads round with Sofinnova Ventures, investing $11 million and taking an 11.2 percent ownership stake in the San Diego-based firm.
Stem CentRx posits that cancer is caused by stem cells gone awry - and is developing antibody drug conjugate therapies to help attack cancer at its root. The Peter Thiel-backed "unicorn" startup is valued at some $3 billion.
A Bay Area startup is harnessing the haute monoclonal antibody technology to develop treatment for psoriasis, cancers and inflammatory disease, and is likely about to kick off some serious late-stage efficacy trials. AbGenomics is in the midst of a $24.5 million fundraising round, according to regulatory filings, and has raised $13.2 million to date. The company […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.